Matthew Paul Kowalsky Form 3 Sigilon Therapeutics / Matthew Paul Kowalsky ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Kowalsky Matthew Paul

(Last) (First) (Middle)

C/O SIGILON THERAPEUTICS, INC.

100 BINNEY STREET STE 600

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/28/2023

3. Issuer Name and Ticker or Trading Symbol
Sigilon Therapeutics, Inc. [ SGTX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
CHIEF OF STAFF AND CLO

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	19,683(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(2)	06/05/2029	Common Stock	77,777	4.12	D
Stock Option (Right to Buy)	(3)	02/26/2030	Common Stock	1,110	9.39	D
Stock Option (Right to Buy)	(4)	02/10/2031	Common Stock	50,000	39.81	D
Stock Option (Right to Buy)	(5)	01/02/2032	Common Stock	90,000	3.03	D
Stock Option (Right to Buy)	(6)	02/17/2032	Common Stock	105,000	1.48	D

Explanation of Responses:

1. Includes 10,000 restricted stock units that vest as to 25% on October 29, 2023, which is the second anniversary of the date of grant, and 75% on the third anniversary of the date of grant, subject to the grantee's continued service to the Company on each vesting date.

2. The option vested as to 25% of the underlying shares of common stock on May 6, 2020, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested.

3. The option vested as to 50% of the underlying shares of common stock on October 23, 2020, based on the Company's satisfaction of certain performance criteria. The option vested as to 50% of the underlying shares of common stock on October 23, 2021, the first anniversary of the vesting commencement date.

4. The option vested as to 25% of the underlying shares of common stock on February 11, 2022, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested.

5. The option vested as to 30% of the underlying shares of common stock on January 3, 2023, the first anniversary of the vesting commencement date, and 70% on January 3, 2024.

6. The option vested as to 25% of the underlying shares of common stock on February 18, 2023, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested.

	/s/ Matthew Kowalsky	02/28/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.